Literature DB >> 14607313

The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

Wanda Lojkowska1, Danuta Ryglewicz, Tomasz Jedrzejczak, Sławomira Minc, Teresa Jakubowska, Halina Jarosz, Anna Bochynska.   

Abstract

The effects of therapy with cholinesterase inhibitors (ChE-I) on regional cerebral blood flow (rCBF) disturbances were investigated by means of single photon emission computed tomography (SPECT). The changes in rCBF were compared with the results of the medical examination and neuropsychological tests. The sample consisted of 41 patients with the Alzheimer's dementia (AD) and vascular dementia (VaD). The effect of ChE-I (rivastigmine) treatment was studied on 33 patients, while the nontreated control group consisted of 8 patients. In the treated patients, an increase in the rCBF was observed, while the scores of the neuropsychological tests decreased slightly. In the VaD group, the increase in rCBF was more significant in the frontal regions, whereas in the group with AD in the temporal regions, respectively. In the nontreated patients, a decrease of both rCBF and scores of neuropsychological tests were observed. The scores of the neuropsychological tests correlated with the results of rCBF. Increased levels of acetylcholine in the brain after ChE-I treatment may support the cholinergic regulation of rCBF, and in result increase it. Such effects seem to be more pronounced in the more affected brain regions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607313     DOI: 10.1016/s0022-510x(03)00229-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

Review 1.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

2.  Intermittent Stimulation of the Nucleus Basalis of Meynert Improves Working Memory in Adult Monkeys.

Authors:  Ruifeng Liu; Jonathan Crawford; Patrick M Callahan; Alvin V Terry; Christos Constantinidis; David T Blake
Journal:  Curr Biol       Date:  2017-08-17       Impact factor: 10.834

Review 3.  Biomarkers in translational research of Alzheimer's disease.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  Neuropharmacology       Date:  2010-04-13       Impact factor: 5.250

4.  Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS.

Authors:  S G Mueller; N Schuff; M W Weiner
Journal:  NMR Biomed       Date:  2006-10       Impact factor: 4.044

5.  The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition.

Authors:  Whitney Wharton; Carey E Gleason; N Maritza Dowling; Cynthia M Carlsson; Eliot A Brinton; M Nanette Santoro; Genevieve Neal-Perry; Hugh Taylor; Frederick Naftolin; Rogerio A Lobo; George Merriam; Joann E Manson; Marcelle I Cedars; Virginia M Miller; Dennis M Black; Matthew Budoff; Howard N Hodis; S Mitchell Harman; Sanjay Asthana
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 6.  Cerebrovascular reactivity to carbon dioxide in Alzheimer's disease.

Authors:  Lidia Glodzik; Catherine Randall; Henry Rusinek; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 7.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

8.  Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.

Authors:  J R Ellis; P J Nathan; V L Villemagne; R S Mulligan; T Saunder; K Young; C L Smith; J Welch; M Woodward; K A Wesnes; G Savage; C C Rowe
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

Review 9.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 10.  Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.

Authors:  Benjamin Lam; Elizabeth Hollingdrake; James L Kennedy; Sandra E Black; Mario Masellis
Journal:  Hum Genomics       Date:  2009-12       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.